Cargando…
The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
INTRODUCTION: The phase 3 trial PALISADE, comparing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) oral immunotherapy versus placebo in peanut-allergic children, reported that a significantly higher percentage of PTAH-treated participants tolerated higher doses of peanut protein after 1 year...
Autores principales: | Yu, Shengsheng, Smith, Alex, Hass, Steve, Wu, Eric, Chai, Xinglei, Zhou, Jenny, Ayyagari, Rajeev, Liu, Jun S., Robison, Dan, Donelson, Sarah M., Tilles, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264172/ https://www.ncbi.nlm.nih.gov/pubmed/34236672 http://dx.doi.org/10.1007/s12325-021-01843-2 |
Ejemplares similares
-
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States
por: Blaiss, Michael S, et al.
Publicado: (2021) -
Qualitative interviews to understand health care providers’ experiences of prescribing licensed peanut oral immunotherapy
por: Anagnostou, Aikaterini, et al.
Publicado: (2022) -
The Peanut Allergy Burden Study: Impact on the quality of life of patients and caregivers
por: Nowak-Wegrzyn, Anna, et al.
Publicado: (2021) -
Treatment of allergic reactions to peanut in recent versus initial reaction
por: Ben-Shoshan, Moshe, et al.
Publicado: (2010) -
The Peanut Allergy Burden Study: Real-world impact of peanut allergy on resource utilization and productivity
por: McCann, William, et al.
Publicado: (2021)